At this point we really can't say if it's our company, or more properly our company's partner, BioChemPharma.
To my knowledge, to date Apoptosis emphasis has been providing BioChem with the screens they need to develop new drugs utilizing apoptosis. They may be developing drugs themselves as well, but I think if they are, their target for going to trials is much later then the lead drug from BioChemPharma.
If Murphy's company is BioChemPharma, that would be a major plus for us, if he's right.
If its the same one I got, my guess is that its Geron. Not to crow, but I had a nice run from to 4.5 to 14 over a few months last year, but missed the peak at 22 the day before I sold. I'm still hot for it, though, if it drifts back down below 10.
I'm leery about Mike Murphy, though. Have you followed his picks over the years. Yikes. And what about his bizarre past? IMO! -BB